Hansa Biopharma AB Share Price BOERSE MUENCHEN

Equities

24H

SE0002148817

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN 14:43:08 29/05/2024 BST 5-day change 1st Jan Change
3.75 EUR +1.74% Intraday chart for Hansa Biopharma AB +7.15% +51.19%

Financials

Sales 2024 * 239M 22.51M 20.75M 1.77B Sales 2025 * 343M 32.24M 29.72M 2.53B Capitalization 2.66B 250M 231M 19.63B
Net income 2024 * -735M -69.15M -63.76M -5.43B Net income 2025 * -712M -66.99M -61.76M -5.26B EV / Sales 2024 * 13.1 x
Net Debt 2024 * 474M 44.59M 41.12M 3.5B Net Debt 2025 * 733M 69M 63.61M 5.41B EV / Sales 2025 * 9.9 x
P/E ratio 2024 *
-3.65 x
P/E ratio 2025 *
-4.33 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
1 week+7.15%
Current month+50.57%
1 month+60.26%
3 months+31.27%
6 months+65.89%
Current year+51.19%
More quotes
1 week
3.30
Extreme 3.298
3.85
1 month
2.30
Extreme 2.302
3.85
3 years
1.79
Extreme 1.794
15.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 19/03/18
Chief Tech/Sci/R&D Officer 53 11-30
Chief Tech/Sci/R&D Officer 66 28/05/20
Members of the board TitleAgeSince
Director/Board Member 73 28/05/18
Chairman 61 29/06/22
Director/Board Member 59 21/05/19
More insiders
Date Price Change
29/05/24 3.75 +1.74%
28/05/24 3.686 +6.66%
27/05/24 3.456 -3.25%
24/05/24 3.572 -4.13%
23/05/24 3.726 +2.87%

Real-time BOERSE MUENCHEN, May 29, 2024 at 02:43 pm

More quotes
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
42.1 SEK
Average target price
105 SEK
Spread / Average Target
+149.41%
Consensus